Scarica l'app Stockscreener
506.61
0.50%
-2.435
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR
Vertex Pharmaceuticals’ SWOT analysis: stock poised for growth amid challenges - Investing.com
JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $512 From $500, Keeps Overweight Rating - Marketscreener.com
Jim Cramer on Vertex (VRTX): “A Revolutionary Anti-Pain Drug” - Insider Monkey
Jim Cramer on Vertex (VRTX): "A Revolutionary Anti-Pain Drug" - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Insider Sell: David Altshuler Sells Shares of Vertex Pharmaceuti - GuruFocus.com
Insider Sell: David Altshuler Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus.com
Should You Buy Vertex Pharmaceuticals Stock At $510? - Trefis
Vertex Pharmaceuticals (VRTX) Rises But Trails Market: What Investors Should Know - Yahoo Finance
Cystic Fibrosis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Is Vertex Pharmaceuticals (VRTX) the Best Diabetes Stock to Buy According to Billionaires? - Insider Monkey
Global mRNA-based Vaccines and Therapeutics Market is expected to Grow at a decent CAGR during the Study Period (2019-2032) | DelveInsight - The Globe and Mail
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack - Yahoo Finance
Ed Kaye, founding CEO of Stoke Therapeutics, steps down - The Business Journals
Vertex Pharmaceuticals (VRTX): One of the Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Vertex's Pain Drug: Big Pharma's Next Major Success? - MSN
Is Vertex Pharmaceuticals (VRTX) Among the Best High Growth Stocks? - Insider Monkey
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock? - Yahoo Finance
DA Davidson maintains Buy on Vertex shares, target $34 By Investing.com - Investing.com UK
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation - The Motley Fool
13 High Growth Large Cap Stocks To Invest In - Insider Monkey
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain - Business Wire
Layoff Tracker: GRO Biosciences Cuts Staff Amid Quest for Strategic Alternatives - BioSpace
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today - Yahoo Finance
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today - Benzinga
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics - Benzinga
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Upgraded by StockNews.com - Defense World
Vertex Pharmaceuticals EVP sells $1.6 million in stock By Investing.com - Investing.com Australia
Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals EVP sells $1.62 million in stock - Investing.com India
Vertex Pharmaceuticals EVP sells $1.6 million in stock - Investing.com
Vertex Pharmaceuticals Executives Sell Shares - TradingView
Vertex Pharmaceuticals CFO sells shares worth $1.65 million - Investing.com
Why Vertex Pharmaceuticals Incorporated (VRTX) is the Best Pharma Stock to Buy According to Hedge Funds - Insider Monkey
Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio? - MSN
Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report? - Yahoo Finance
Where Will Vertex Pharmaceuticals Be in 10 Years? - sharewise
Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA - PMLiVE
3 Reasons to Avoid VRTX and 1 Stock to Buy Instead - Yahoo Finance
Rep. Jefferson Shreve Purchases Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Defense World
Vertex at Leerink: Strategic Moves and Growth Prospects - Investing.com
UK MHRA approves Vertex’s Alyftrek for cystic fibrosis - Pharmaceutical Business Review
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Jones Financial Companies Lllp - Defense World
UnitedHealth slots Vertex's non-opioid pain med at top of tiered formulary - FirstWord Pharma
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies - Benzinga
Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment - Yahoo Finance
Vertex Pharmaceuticals Says Journavx Non-Opioid Pain Killer Added to Optum Formulary - Marketscreener.com
Vertex Announces UK Mhra Approval Of Alyftrek -March 07, 2025 at 11:32 am EST - Marketscreener.com
Vertex Pharmaceuticals Gets UK Regulatory Approval for Alyftrek to Treat Cystic Fibrosis - Marketscreener.com
(Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
0.56%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):